Modified HSV-2 Oncolytic Virus for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic herpes simplex viruses, particularly those derived from HSV-1, have limited anti-tumor activity and are restricted by the body's innate immunity and neutralizing antibodies, necessitating the development of a more potent and immune-evasive oncolytic agent for effective cancer treatment.
Innovation Solution
A modified Herpes Simplex Virus Type 2 (HSV-2) with a modified ICP10 gene, encoding a polypeptide that lacks protein kinase activity but retains ribonucleotide reductase activity, is engineered to selectively replicate in tumor cells, induce cell membrane fusion, and trigger apoptosis, enhancing its anti-tumor potency and immune evasion capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HSV-1 is used as an oncolytic virus, then it can replicate in tumor cells, but it is restricted by the body's innate immunity and neutralizing antibodies, reducing its anti-tumor activity
Solution Approach 1:
The patent extracts the essential replication function from HSV-1 and transfers it to HSV-2. Specifically, the ICP10 gene (encoding ribonucleotide reductase large subunit) from HSV-1 is cloned and expressed in HSV-2, enabling the HSV-2-based oncolytic virus to replicate in tumor cells without being subject to the same immune restrictions as HSV-1
Solution Approach 2:
The patent creates a functional copy of the ICP10 gene product in a different viral system. By expressing the HSV-1 ICP10 gene in HSV-2, the invention copies the critical replication function while using a different viral backbone that is less restricted by human innate immunity, thereby achieving similar anti-tumor effects with improved immune evasion
2Power
If the ICP10 gene is modified to enhance replication in tumor cells, then anti-tumor potency increases, but the virus may lose ability to replicate in normal cells, reducing safety
Solution Approach 1:
The patent applies local quality by using a tumor-specific promoter (such as the cytomegalovirus immediate-early promoter or other tumor-selective promoters) to drive expression of the ICP10 gene only in tumor cells. This ensures that the enhanced replication capability is localized to the tumor environment while leaving normal cells unaffected, thereby maintaining safety while increasing anti-tumor potency
Solution Approach 2:
The patent changes the expression parameters of the ICP10 gene by controlling its transcription through tumor-specific regulatory elements. By modifying the promoter region and expression conditions, the virus achieves high-level ICP10 expression specifically in tumor cells (enhancing potency) while maintaining low or no expression in normal cells (ensuring safety)
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified HSV-2 demonstrates significantly improved anti-tumor activity, including enhanced cell killing and immune response, with reduced toxicity and increased efficacy against various cancer types, both in vitro and in vivo, compared to traditional oncolytic viruses.
Implementation Method 1
The modified ICP10 polypeptide has ribonucleotide reductase activity, but lacks protein kinase activity
Implementation Method 2
induce cell membrane fusion, and trigger apoptosis, enhancing its anti-tumor potency and immune evasion capabilities
Data Source
AI summary
The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.